ALK and non-small cell lung carcinoma: The phase III randomized trial, including 275 patients with advanced treatment-naïve ALK-positive NSCLC, revealed that brigatinib produced better PFS outcomes than crizotinib (12-month PFS rate: 67 percent versus 43 percent; HR 0.49, 95% CI 0.33–0.74) after a median follow-up of 9–11 months [14].